Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, UK.
Clin Endocrinol (Oxf). 2020 Sep;93(3):269-279. doi: 10.1111/cen.14218. Epub 2020 Jun 5.
Maturity onset diabetes of the young due to variants in HNF1A (HNF1A-MODY) is the most common form of monogenic diabetes. Individuals with HNF1A-MODY usually have a lean phenotype which contrasts with type 2 diabetes (T2DM). Data from hepatocytes derived from Hnf1a knock-out mice demonstrated dysregulation of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which regulates glucocorticoid availability and action in target tissues, together with 11β-HSD2 and steroid A-ring reductases, 5α- and 5β-reductase. We proposed that altered glucocorticoid metabolism might underpin some of the phenotypic differences between patients with HNF1A-MODY and those with T2DM.
A retrospective matched cohort study.
24-hours urine steroid metabolome profiling was carried out by gas chromatography-mass spectrometry in 35 subjects with HNF1A-MODY, 35 individuals with T2DM and 35 healthy controls matched for age, sex and BMI. The steroid metabolites were expressed as μg/L in all groups and measured in mid-morning urine in diabetic subjects and 24-hour urine collection in healthy controls. Hence, only ratios were compared not the individual steroids. Established ratios of glucocorticoid metabolites were used to estimate 11β-HSD1/2 and 5α- and 5β-reductase activities.
While 11β-HSD1 activity was similar in all groups, 11β-HSD2 activity was significantly lower in subjects with HNF1A-MODY and T2DM than in healthy controls. The ratio of 5β- to 5α-metabolites of cortisol was higher in subjects with HNF1A-MODY than in T2DM and healthy controls, probably due to increased activity of the 5β-reductase (AKR1D1) in HNF1A-MODY.
This is the first report of steroid metabolites in HNF1A-MODY. We have identified distinct differences in steroid metabolism pathways in subjects with HNF1A-MODY that have the potential to alter steroid hormone availability. Further studies are required to explore whether these changes link to phenotype.
由于 HNF1A 变异导致的青少年发病的成年型糖尿病(HNF1A-MODY)是最常见的单基因糖尿病形式。HNF1A-MODY 患者通常具有瘦体型,与 2 型糖尿病(T2DM)形成对比。来自 Hnf1a 敲除小鼠的肝细胞数据表明,11β-羟类固醇脱氢酶 1(11β-HSD1)的调节紊乱,该酶调节糖皮质激素在靶组织中的可用性和作用,以及 11β-HSD2 和甾体 A 环还原酶、5α-和 5β-还原酶。我们假设改变的糖皮质激素代谢可能是 HNF1A-MODY 患者和 T2DM 患者之间一些表型差异的基础。
回顾性匹配队列研究。
通过气相色谱-质谱法对 35 名 HNF1A-MODY 患者、35 名 T2DM 患者和 35 名年龄、性别和 BMI 匹配的健康对照者的 24 小时尿液类固醇代谢组进行了分析。在所有组中,类固醇代谢物均以μg/L 表示,并在糖尿病患者的中上午尿液和健康对照者的 24 小时尿液采集时进行测量。因此,仅比较了比值而不是个体类固醇。使用已建立的糖皮质激素代谢物比值来估计 11β-HSD1/2 和 5α-和 5β-还原酶活性。
虽然所有组中 11β-HSD1 活性相似,但 HNF1A-MODY 和 T2DM 患者的 11β-HSD2 活性明显低于健康对照组。HNF1A-MODY 患者的皮质醇 5β-代谢物与 5α-代谢物的比值高于 T2DM 和健康对照组,这可能是由于 HNF1A-MODY 中 5β-还原酶(AKR1D1)活性增加所致。
这是 HNF1A-MODY 中类固醇代谢物的首次报道。我们已经确定了 HNF1A-MODY 患者中类固醇代谢途径的明显差异,这些差异有可能改变类固醇激素的可用性。需要进一步研究以探讨这些变化是否与表型相关。